NASDAQ:CMPS COMPASS Pathways (CMPS) Stock Forecast, Price & News $7.88 +0.29 (+3.82%) (As of 06/2/2023 ET) Add Compare Share Share Today's Range$7.60▼$7.9750-Day Range$7.34▼$10.6952-Week Range$6.97▼$21.50Volume173,863 shsAverage Volume171,802 shsMarket Capitalization$335.92 millionP/E RatioN/ADividend YieldN/APrice Target$34.83 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media COMPASS Pathways MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside496.4% Upside$47.00 Price TargetShort InterestBearish6.40% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.63Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($2.60) to ($2.89) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.69 out of 5 starsMedical Sector821st out of 983 stocksPharmaceutical Preparations Industry414th out of 486 stocks 3.5 Analyst's Opinion Consensus RatingCOMPASS Pathways has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $47.00, COMPASS Pathways has a forecasted upside of 496.4% from its current price of $7.88.Amount of Analyst CoverageCOMPASS Pathways has only been the subject of 2 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted6.40% of the outstanding shares of COMPASS Pathways have been sold short.Short Interest Ratio / Days to CoverCOMPASS Pathways has a short interest ratio ("days to cover") of 10.2, which indicates bearish sentiment.Change versus previous monthShort interest in COMPASS Pathways has recently decreased by 0.36%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldCOMPASS Pathways does not currently pay a dividend.Dividend GrowthCOMPASS Pathways does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CMPS. Previous Next 2.0 News and Social Media Coverage News SentimentCOMPASS Pathways has a news sentiment score of 0.63. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for COMPASS Pathways this week, compared to 2 articles on an average week.Search InterestOnly 8 people have searched for CMPS on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.MarketBeat FollowsOnly 11 people have added COMPASS Pathways to their MarketBeat watchlist in the last 30 days. This is a decrease of -8% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, COMPASS Pathways insiders have not sold or bought any company stock.Percentage Held by Insiders24.85% of the stock of COMPASS Pathways is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 17.54% of the stock of COMPASS Pathways is held by institutions. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for COMPASS Pathways are expected to decrease in the coming year, from ($2.60) to ($2.89) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of COMPASS Pathways is -3.53, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of COMPASS Pathways is -3.53, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCOMPASS Pathways has a P/B Ratio of 2.08. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About COMPASS Pathways (NASDAQ:CMPS) StockCOMPASS Pathways plc operates as a mental health care company primarily in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that has completed Phase IIb clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom.Read More Receive CMPS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for COMPASS Pathways and its competitors with MarketBeat's FREE daily newsletter. Email Address CMPS Stock News HeadlinesMay 31, 2023 | finance.yahoo.comCOMPASS Pathways’ Co-Founder Ekaterina Malievskaia to Step Down as Chief Innovation OfficerMay 30, 2023 | markets.businessinsider.comNuminus' Clinical Site Joins Compass' Phase 3 Program On Psilocybin Therapy For TRDJune 4, 2023 | Legacy Research (Affiliate) (Ad)Sell Every Stock, Except ONE (Ticker Revealed)We saw one of the longest bull markets in history, with the S&P surging well over 800% But now the chickens have come home to roost. However, Jeff Clark couldn’t care less because he ignores almost every single stock in the market.May 28, 2023 | benzinga.comCompass Pathways Stock (NASDAQ:CMPS), Insider Trading ActivityMay 26, 2023 | markets.businessinsider.comTrial Gives Cancer Patients 18 Months Of Robust Benefits After One Psilocybin SessionMay 26, 2023 | finance.yahoo.comCOMPASS Pathways to participate in upcoming Jefferies Healthcare ConferenceMay 26, 2023 | finance.yahoo.comData Demonstrating Long-Term Improvement in Depression in Cancer Patients Following Single Dose of COMP360 Psilocybin Therapy to be Presented at ASCO 2023May 17, 2023 | americanbankingnews.comCOMPASS Pathways plc (NASDAQ:CMPS) Forecasted to Earn Q2 2023 Earnings of ($0.74) Per ShareJune 4, 2023 | Legacy Research (Affiliate) (Ad)Sell Every Stock, Except ONE (Ticker Revealed)We saw one of the longest bull markets in history, with the S&P surging well over 800% But now the chickens have come home to roost. However, Jeff Clark couldn’t care less because he ignores almost every single stock in the market.May 15, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Zynerba Pharmaceuticals (ZYNE) and COMPASS Pathways (CMPS)May 13, 2023 | markets.businessinsider.comCOMPASS Pathways (CMPS) Gets a Buy from Maxim GroupMay 11, 2023 | markets.businessinsider.comExpert Ratings for Compass PathwaysMay 11, 2023 | finance.yahoo.comCompass Pathways Plc (CMPS) Q1 2023 Earnings Call TranscriptMay 11, 2023 | finance.yahoo.comCOMPASS Pathways Announces First Quarter 2023 Financial Results and Business HighlightsMay 10, 2023 | msn.comCOMPASS Pathways ADS Q1 2023 Earnings PreviewMay 10, 2023 | americanbankingnews.comCOMPASS Pathways (CMPS) to Release Earnings on ThursdayMay 8, 2023 | msn.comPsyched: Psychedelics Reimbursement, Amanita Muscaria Boom, $53M Material Breach Lawsuit & MoreMay 6, 2023 | finance.yahoo.comThis Regulatory Change Means Psychedelic Stocks Are One Step Closer to Being a Buy. Here's WhyMay 3, 2023 | finance.yahoo.comCOMPASS Pathways plc to announce first quarter 2023 financial results on 11 May 2023May 2, 2023 | msn.comEXCLUSIVE: AMA Moves Toward Psychedelic Therapy Reimbursement, Filing A Gap In RegulationsMay 2, 2023 | finance.yahoo.comAmerican Medical Association to Issue First New Code for Psychedelic TherapiesApril 21, 2023 | marketwatch.com8-K: COMPASS Pathways plcApril 20, 2023 | finance.yahoo.comAfter Falling 60% in 1 Year, Is Atai Life Sciences Stock Still a Buy?April 15, 2023 | americanbankingnews.comEF Hutton Acquisition Co. I Reaffirms Buy Rating for COMPASS Pathways (NASDAQ:CMPS)April 13, 2023 | msn.comEF Hutton Reiterates COMPASS Pathways Plc American Depository Shares (CMPS) Buy RecommendationApril 12, 2023 | seekingalpha.comCOMPASS Pathways: Cash Burn Rate Overshadows Positive Trial ProgressApril 12, 2023 | markets.businessinsider.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Incyte (INCY) and COMPASS Pathways (CMPS)See More Headlines CMPS Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CMPS Company Calendar Last Earnings11/08/2021Today6/03/2023Next Earnings (Estimated)8/03/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CMPS CUSIPN/A CIK1816590 Webwww.compasspathways.com Phone716-676-6461FaxN/AEmployees116Year Founded2016Price Target and Rating Average Stock Price Forecast$47.00 High Stock Price Forecast$120.00 Low Stock Price Forecast$19.00 Forecasted Upside/Downside+342.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($2.23) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-91,500,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-49.62% Return on Assets-45.36% Debt Debt-to-Equity RatioN/A Current Ratio14.91 Quick Ratio14.91 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.79 per share Price / Book2.08Miscellaneous Outstanding Shares42,630,000Free Float32,038,000Market Cap$335.92 million OptionableNot Optionable Beta2.50 Social Links Key ExecutivesMr. George Jay Goldsmith (Age 68)Exec. Chairman & Co-Founder Comp: $943.52kDr. Ekaterina Malievskaia M.D. (Age 55)Co-Founder, Chief Innovation Officer & Exec. Director Comp: $669.13kDr. Guy GoodwinChief Medical OfficerMr. Kabir Nath M.A.M.B.A., Chief Exec. OfficerMr. Michael F. Falvey (Age 63)Chief Financial Officer Dr. Greg Ryslik Ph.D.Exec. VP of AI, Engineering, Digital Health Research & TechnologyMr. Stephen D. SchultzSr. VP of Investor RelationsMr. Matthew OwensGen. Counsel & Chief Legal OfficerMr. Christopher WilliamsChief Communications OfficerMs. Anne BenedictChief People OfficerMore ExecutivesKey CompetitorsKalVista PharmaceuticalsNASDAQ:KALVTheseus PharmaceuticalsNASDAQ:THRXPrecigenNASDAQ:PGENDesign TherapeuticsNASDAQ:DSGNAstria TherapeuticsNASDAQ:ATXSView All CompetitorsInstitutional OwnershipPutnam Investments LLCBought 71,964 shares on 5/22/2023Ownership: 0.572%State Street CorpBought 88,028 shares on 5/16/2023Ownership: 0.245%Susquehanna International Group LLPSold 322,800 shares on 5/16/2023Ownership: 0.000%Sculptor Capital LPBought 19,200 shares on 5/16/2023Ownership: 0.000%Two Sigma Advisers LPSold 49,900 shares on 5/15/2023Ownership: 0.193%View All Institutional Transactions CMPS Stock - Frequently Asked Questions Should I buy or sell COMPASS Pathways stock right now? 5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for COMPASS Pathways in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" CMPS shares. View CMPS analyst ratings or view top-rated stocks. What is COMPASS Pathways' stock price forecast for 2023? 5 equities research analysts have issued twelve-month price objectives for COMPASS Pathways' stock. Their CMPS share price forecasts range from $19.00 to $120.00. On average, they predict the company's stock price to reach $47.00 in the next year. This suggests a possible upside of 496.4% from the stock's current price. View analysts price targets for CMPS or view top-rated stocks among Wall Street analysts. How have CMPS shares performed in 2023? COMPASS Pathways' stock was trading at $8.03 at the start of the year. Since then, CMPS stock has decreased by 1.9% and is now trading at $7.88. View the best growth stocks for 2023 here. When is COMPASS Pathways' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023. View our CMPS earnings forecast. How were COMPASS Pathways' earnings last quarter? COMPASS Pathways plc (NASDAQ:CMPS) announced its quarterly earnings results on Monday, November, 8th. The company reported ($0.38) EPS for the quarter, topping analysts' consensus estimates of ($0.49) by $0.11. What ETFs hold COMPASS Pathways' stock? ETFs with the largest weight of COMPASS Pathways (NASDAQ:CMPS) stock in their portfolio include AdvisorShares Psychedelics ETF (PSIL), ARK Genomic Revolution ETF (ARKG), Subversive Mental Health ETF (SANE), Virtus LifeSci Biotech Clinical Trials ETF (BBC), Putnam Sustainable Future ETF (PFUT), Grizzle Growth ETF (GRZZ), ALPS Medical Breakthroughs ETF (SBIO) and iShares Biotechnology ETF (IBB). What other stocks do shareholders of COMPASS Pathways own? Based on aggregate information from My MarketBeat watchlists, some companies that other COMPASS Pathways investors own include Nikola (NKLA), Vaxart (VXRT), Beyond Meat (BYND), Evofem Biosciences (EVFM), GrowGeneration (GRWG), McDonald's (MCD), Plug Power (PLUG), Block (SQ), Workhorse Group (WKHS) and When did COMPASS Pathways IPO? (CMPS) raised $100 million in an initial public offering on Friday, September 18th 2020. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. Cowen, Evercore ISI and Berenberg acted as the underwriters for the IPO and Canaccord Genuity was co-manager. What is COMPASS Pathways' stock symbol? COMPASS Pathways trades on the NASDAQ under the ticker symbol "CMPS." Who are COMPASS Pathways' major shareholders? COMPASS Pathways' stock is owned by a variety of institutional and retail investors. Top institutional investors include ARK Investment Management LLC (5.96%), Sumitomo Mitsui Trust Holdings Inc. (0.91%), Nikko Asset Management Americas Inc. (0.91%), Barclays PLC (0.80%), BlackRock Inc. (0.62%) and Putnam Investments LLC (0.57%). Insiders that own company stock include David Y Norton and Ekaterina Malievskaia. View institutional ownership trends. How do I buy shares of COMPASS Pathways? Shares of CMPS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is COMPASS Pathways' stock price today? One share of CMPS stock can currently be purchased for approximately $7.88. How much money does COMPASS Pathways make? COMPASS Pathways (NASDAQ:CMPS) has a market capitalization of $335.92 million. The company earns $-91,500,000.00 in net income (profit) each year or ($2.23) on an earnings per share basis. How many employees does COMPASS Pathways have? The company employs 116 workers across the globe. How can I contact COMPASS Pathways? The official website for the company is www.compasspathways.com. The company can be reached via phone at 716-676-6461 or via email at ir@compasspathways.com. This page (NASDAQ:CMPS) was last updated on 6/4/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding COMPASS Pathways plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.